



PATENT APPLICATION

03CO

Box/seq.  
#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Yoshinaga et al.

Serial No.: 09/728,420

Filed: November 28, 2000

For: Novel Polypeptides Involved in Immune Response

Docket No.: A-579C

RESPONSE TO NOTICE TO COMPLY  
AND  
ATTORNEY'S STATEMENT PURSUANT TO 37 CFR § 1.821

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This is in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated June 7, 2001.

I hereby state that the substitute paper copy and computer readable form (CRF) of the "Sequence Listing" submitted herewith for the above-mentioned patent application are the same, and contain no new matter.

Respectfully submitted,

Robert B. Winter  
Attorney/Agent for Applicant(s)  
Registration No.: 34,458  
Phone: (805) 447-2425  
Date: *JUNE 27, 2001*

Please send all future correspondence to:

U.S. Patent Operations/RBW  
Dept. 4300, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

June 28, 2001  
Date

D. Dillon  
Signature

09728420-070201